Projects per year
Background: Studies on a new coronavirus disease (COVID-19) show the elevation of liver enzymes and liver fibrosis index (FIB-4) independently on pre-existing liver diseases. It points to increased liver fibrogenesis during acute COVID-19 with possible long-term consequences. This study aimed to assess liver fibrosis in COVID-19 patients by serum hyaluronic acid (HA) and FIB-4. Methods: The study included the acute COVID-19 group (66 patients, 50% females, mean age 58.3 ± 14.6), the post-COVID group (58 patients in 3–6 months after the recovery, 47% females, mean age 41.2 ± 13.4), and a control group (17 people, 47% females, mean age 42.8 ± 11.0). Ultrasound elastography was performed in the post-COVID and control groups. Results: Sixty-five percent of the acute COVID-19 group had increased FIB-4 (> 1.45), and 38% of patients had FIB-4 ≥ 3.25. After matching by demographics, 52% of acute COVID-19 and 5% of the post-COVID group had FIB-4 > 1.45, and 29% and 2% of patients had FIB-4 ≥ 3.25, respectively. Increased serum HA (≥ 75 ng/ml) was observed in 54% of the acute COVID-19 and 15% of the post-COVID group. In the acute COVID-19 group, HA positively correlated with FIB-4, AST, ALT, LDH, IL-6, and ferritin and negatively with blood oxygen saturation. In the post-COVID group, HA did not correlate with FIB-4, but it was positively associated with higher liver stiffness and ALT. Conclusion: More than half of acute COVID-19 patients had increased serum HA and FIB-4 related to liver function tests, inflammatory markers, and blood oxygen saturation. It provides evidence for the induction of liver fibrosis by multiple factors during acute COVID-19. Findings also indicate possible liver fibrosis in about 5% of the post-COVID group.
|Number of pages||9|
|Publication status||Published - Dec 2021|
- Liver fibrosis index
- Hyaluronic acid
- Serological biomarker
Field of Science*
- 3.2 Clinical medicine
- 1.1. Scientific article indexed in Web of Science and/or Scopus database
FingerprintDive into the research topics of 'Intriguing findings of liver fibrosis following COVID-19'. Together they form a unique fingerprint.
- 1 Finished
Clinical, biochemical, immunogenetic paradigms of Covid-19 infection and their correlation with socio-demographic, etiological, pathogenetic, diagnostic, therapeutically and prognostically important factors to be included in guidelines
Vīksna, L., Leja, M., Murovska, M., Gardovska, D., Koļesova, O., Laivacuma, S., Platkājis, A., Eglīte, J., Šķesters, A., Radziņa, M., Stūre, G., Zavadska, D., Storoženko, J., Rozentāle, B., Zeltiņa, I., Koļesovs, A., Nora-Krūkle, Z., Grāvelsiņa, S., Karelis, G., Sperga, M., Plaudis, H., Arāja, D., Dzīvīte-Krišāne, I., Aleksejeva, E., Puķīte, I., Grantiņa, I., Ivanova, V., Ivanovs, A., Arutjuņana, S., Vanaga, I., Kustovs, D., Čistjakovs, M., Strojeva, S., Sokolovska, L., Meiere, A., Bajāre, L. & Vilmane, A.
1/07/20 → 30/06/21
Project: National Research Programme
Markers of liver fibrogenesis in patients with COVID-19
Vīksna, L. (Creator), Koļesova, O. (Creator), Koļesovs, A. (Creator), Vanaga, I. (Creator), Radziņa, M. (Creator) & Arutjuņana, S. (Creator), Riga Stradins University, 10 May 2021
DOI: doi:10.48510/FK2/B4HPSJ, https://dataverse.rsu.lv/dataset.xhtml?persistentId=doi:10.48510/FK2/B4HPSJ